View Older Stories View More Recent Stories

Feb 3, 2023 06:59AM Bristol Myers Squibb to Participate in the Guggenheim Healthcare Talks 2023 Oncology Conference
Feb 2, 2023 06:59AM Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022
Jan 27, 2023 07:06AM Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion for Reblozyl for Adult Patients with Anemia-Associated, NTD Beta Thalassemia
Jan 27, 2023 07:05AM Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Adult Patients with Anemia-Associated, Non-Transfusion-Dependent (NTD) Beta Thalassemia
Jan 27, 2023 06:59AM Bristol-Myers Squibb (BMY) Reports Positive CHMP Opinion for Once-Daily Sotyktu
Jan 27, 2023 06:59AM Bristol Myers Squibb Announces Positive CHMP Opinion for Once-Daily Sotyktu (deucravacitinib) as a Treatment for Adults With Moderate-to-Severe Plaque Psoriasis
Jan 26, 2023 07:00AM Bristol-Myers Squibb (BMY) Reports TRANSCEND CLL 004 Trial of Breyanzi Met Primary Endpoint
Jan 26, 2023 06:59AM Bristol Myers Squibb Announces TRANSCEND CLL 004 Trial of Breyanzi® (lisocabtagene maraleucel) Met Primary Endpoint of Complete Response Rate in Patients with Relapsed or Refractory Chronic Lymphocyt
Jan 3, 2023 07:05AM Bristol Myers Squibb to Present at J.P. Morgan’s 41st Annual Healthcare Conference
Jan 3, 2023 07:00AM Bristol-Myers Squibb (BMY) completes sale of Syracuse, New York manufacturing facility
Jan 3, 2023 06:59AM Bristol Myers Squibb Completes Sale of Manufacturing Facility in Syracuse, New York
Dec 16, 2022 03:40AM Evotec Achieves Further Progress in Neuroscience Collaboration with Bristol Myers Squibb
Dec 15, 2022 06:59AM Bristol Myers Squibb to Report Results for Fourth Quarter 2022 on February 2, 2023
Dec 12, 2022 06:59AM Bristol Myers Squibb Announces First Disclosures and New Data at ASH 2022, Demonstrating Commitment to Raising Standards in Treatment Through Broad Multiple Myeloma Portfolio
Dec 8, 2022 04:16PM Bristol Myers Squibb Announces Dividend Increase
Nov 29, 2022 08:00AM Envisagenics Announces Research Collaboration with Bristol Myers Squibb
Nov 9, 2022 06:59AM Bristol Myers Squibb to Participate in the Wolfe Research Healthcare Conference
Nov 2, 2022 06:59AM Data Reinforcing Impact of Bristol Myers Squibb Cardiovascular Portfolio to be Presented at American Heart Association Scientific Sessions 2022
Oct 31, 2022 07:02AM Bristol-Myers Squibb (BMY) Announces Phase 3 COMMANDS Trial Met its Primary Endpoint
Oct 31, 2022 06:59AM Bristol Myers Squibb Announces Positive Topline Results of Phase 3 COMMANDS Trial
Oct 27, 2022 08:32AM Bristol-Myers Squibb (BMY) Extends Multi-Year Deal with Obsidian Therapeutics
Oct 27, 2022 08:30AM Obsidian Therapeutics Announces Extension of Multi-Year Collaboration Agreement with Bristol Myers Squibb
Oct 26, 2022 03:36AM Bristol-Myers Squibb (BMY) Reports Q3 Revenue of $11.22B, EPS of $1.99
Oct 26, 2022 03:30AM Bristol-Myers Squibb (BMY) Reports New Zeposia Data Shows COVID-19 Outcomes and Preservation of Long-Term Cognitive Function from Separate Analyses in Patients with Relapsing Forms of Multiple Scleros
Oct 26, 2022 02:00AM New Zeposia (ozanimod) Data Highlight COVID-19 Outcomes and Preservation of Long-Term Cognitive Function from Separate Analyses in Patients with Relapsing Forms of Multiple Sclerosis
Oct 25, 2022 07:31PM Bristol Myers Squibb Reports Third Quarter Financial Results for 2022 
Oct 24, 2022 06:59AM Bristol-Myers Squibb (BMY) Reports New Data Showing Continuous Zeposia (ozanimod) Treatment Prevents Disease Relapse Over One Year in 86.1% of Patients Who Respond at the End of the Induction Period
Oct 24, 2022 06:59AM New Data Presented at the American College of Gastroenterology Annual Scientific Meeting Demonstrate Continuous Zeposia (ozanimod) Treatment Prevents Disease Relapse Over One Year in 86.1% of Patients
Oct 21, 2022 06:59AM Bristol-Myers Squibb (BMY) Announces FDA Accepts sNDA for CAMZYOS in Symptomatic Obstructive Hypertrophic Cardiomyopathy to Reduce the Need for Septal Reduction Therapy
Oct 21, 2022 06:59AM U.S. Food and Drug Administration (FDA) Accepts Supplemental New Drug Application for CAMZYOS® (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy to Reduce the Need for Septal Reduct
Oct 19, 2022 04:30PM Bristol Myers Squibb Presents Data from CheckMate -76K Showing Opdivo (nivolumab) Reduced the Risk of Recurrence or Death by 58% Versus Placebo in Patients with Completely Resected Stage IIB or IIC Me
Oct 7, 2022 06:59AM Bristol Myers Squibb Announces Change to Earnings Conference Call Dial-In Information for Third Quarter 2022 Results Scheduled for October 26, 2022
Oct 4, 2022 08:03AM Exelixis (EXEL) Expands Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb (BMY)
Oct 4, 2022 08:00AM Exelixis Expands Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Include the Fixed-Dose Combination of Nivolumab and Relatlimab in Combination with XL092 in Phase 1b STE
Sep 16, 2022 04:15PM Bristol-Myers Squibb (BMY) Granted EU Approval of Opdualag
Sep 16, 2022 04:15PM Bristol Myers Squibb Receives European Commission Approval for LAG-3-Blocking Antibody Combination, Opdualag (nivolumab and relatlimab), for the Treatment of Unresectable or Metastatic Melanoma with T
Sep 15, 2022 06:59AM Bristol-Myers Squibb (BMY) Reports Adjuvant Treatment with Opdivo Demonstrated Statistically Significant and Clinically Meaningful Improvement in Recurrence-Free Survival (RFS) in Patients with Stage
Sep 15, 2022 06:59AM Bristol Myers Squibb Announces Adjuvant Treatment with Opdivo (nivolumab) Demonstrated Statistically Significant and Clinically Meaningful Improvement in Recurrence-Free Survival (RFS) in Patients wit
Sep 14, 2022 04:16PM Bristol Myers Squibb Announces Dividend
Sep 12, 2022 06:26AM Bristol-Myers Squibb (BMY) Announces FDA Approval for Sotyktu to Treat Moderate-to-Severe Plaque Psoriasis
Sep 12, 2022 05:27AM Bristol-Myers Squibb (BMY) Reports Strong New Sotyktu Data
Sep 10, 2022 02:30AM Bristol Myers Squibb Announces New Sotyktu™ (deucravacitinib) Long-Term Data Showing Clinical Efficacy Maintained for Up to Two Years with Continuous Treatment in Moderate-to-Severe Plaque Psoriasis
Sep 9, 2022 10:38PM   U.S. Food and Drug Administration Approves Sotyktu™ (deucravacitinib), Oral Treatment for Adults with Moderate-to-Severe Plaque Psoriasis
Sep 7, 2022 07:00AM Bristol Myers Squibb Employees to Relay Nearly 3,000 Miles Cross-Country Aspiring to Raise Over $1 Million for the V Foundation for Cancer Research
Sep 7, 2022 06:59AM Bristol Myers Squibb to Report Results for Third Quarter 2022 on October 26, 2022
Sep 6, 2022 06:59AM Bristol Myers Squibb to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
Sep 5, 2022 06:59AM Bristol Myers Squibb Research at ESMO Congress 2022 Highlights Depth of Development Program Across Early- and Late-Stages of Cancer
Aug 31, 2022 06:59AM Bristol Myers Squibb to Participate in Citi’s 17th Annual BioPharma Conference
Aug 28, 2022 03:36AM Late-Breaking Results From Phase 2 AXIOMATIC-SSP Study of Milvexian, an Investigational Oral Factor XIa Inhibitor, Show Favorable Antithrombotic Profile in Combination With Dual Antiplatelet Therapy
Aug 17, 2022 08:32AM Bristol-Myers Squibb (BMY) Completes Acquisition of Turning Point Therapeutics (TPRX)
View More Recent Stories View Older Stories